Atea Pharmaceuticals (AVIR) Assets Average (2020 - 2026)

Atea Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $291.1 million for Q1 2026.

• In Q1 2026, Assets Average fell 35.63% year-over-year to $291.1 million; the TTM figure through Mar 2026 stood at $291.1 million (down 35.63% YoY), while the FY2025 annual figure was $389.9 million, down 26.4% from the prior year.
• Assets Average was $291.1 million for Q1 2026 at Atea Pharmaceuticals, down from $329.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $745.0 million in Q1 2022 to a low of $291.1 million in Q1 2026.
• Historically, Assets Average has averaged $544.8 million across 5 years, with a median of $574.0 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Assets Average decreased 10.44% in 2023, then sank 35.63% in 2026.
• A 5-year view of Assets Average shows it stood at $676.6 million in 2022, then declined by 11.1% to $601.5 million in 2023, then dropped by 20.57% to $477.8 million in 2024, then sank by 31.13% to $329.1 million in 2025, then fell by 11.53% to $291.1 million in 2026.
• The last three Assets Average figures came in at $291.1 million (Q1 2026), $329.1 million (Q4 2025), and $367.3 million (Q3 2025), per Business Quant data.